Figure 4.
TRPV4 channel agonist increases AQP4 cell surface localization in primary human astrocytes. Data are mean fold changes in expression (±SEM) of cells incubated at 32 °C for 4 h (Hypothermia) or 85 mOsm/kg H2O (Hypotonicity) compared with normothermic (Control) astrocytes with or without the potent TRPV4 channel agonist (GSK1016790A) at 2.1 μm. The TRPV4 agonist was added either 30 min before the intervention (Before) or at the same time of the intervention (Together). Kruskal–Wallis with Conover–Inman post hoc analysis tests were used to identify significant differences between samples (n = 4). ***Represents statistical significance (***P < 0.001) using statsdirect 3 software.